ArticleThe Journal of veterinary medical science2026
Pathological features and clinical outcomes of hemangioblastoma in the spinal cord of three dogs.
Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemangioblastomas are rare intramedullary vascular tumors. Their biological nature is considered benign, but there is little information in dogs. This report describes histopathological and immunohistochemical features and postoperative clinical courses of three dogs to expand the current knowledge of this tumor. Histopathological examination revealed the proliferation of neoplastic stromal cells with irregularly arranged blood vessels and clusters of lymphocytes. Immunohistochemically, neoplastic stromal cells were immunolabeled for glial fibrillary acidic protein (GFAP), neuron specific antigen (NSE), and vimentin, and capillary endothelia and vessel walls were immunolabeled for CD31 and smooth muscle actin (SMA). Postoperative follow-up revealed improvements in neurological symptoms and no evidence of tumor recurrence for 3 months to 3 years, suggesting that surgical excision is a beneficial treatment method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.